Bio-Techne

TECH on Nasdaq. Bio-Techne sells life science reagents, instruments, and services to researchers, diagnostic labs, bioprocessing firms. Market value $11.4bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to June 2026.

Should I look at this?

Good business, but not cheap right now

See cheaper Health care stocks on the list

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
2.7%low

For every $100 of what the whole company costs, it produced $2.70 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
47.1×full

You pay 47.1 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to June 2026
9.7%five-year median

Each dollar kept in the business earns 10 cents a year. Above 10 is good.

Quality score: 92 of 100. Price score: 23 of 100. Our list needs 70 on quality and 60 on price.

$72.70 a share, 68% above its 1-year low

Over the past year the price has ranged from $43.20 to $72.88.

Dividend: 0.4% a year

Paid every year for at least 5 years

Price from Thursday’s close (19 November).

Five years of cash, in billions

0.3
0.2
0.2
0.3
0.3
0.3
2022202320242025202612 monthsto Sep '26
Revenue
$1.1bn$1.1bn$1.2bn$1.2bn$1.2bn
Operating margin
26.8%26.3%17.8%8.4%20.7%
Debt to equity
0.150.180.150.180.09
Shares outstanding
0.16bn0.16bn0.16bn0.16bn0.16bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Nothing unusual
  • Financial strength (Piotroski)7 of 9
  • Profit backed by cash (accruals)Yes
  • Debt0.09× equity
  • Revenue growth, five yearsSlow, 5.5% a year
  • Buying back its own sharesRoughly flat

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $300 million last quarter, up 5% on a year ago.
  • Profit: $28 million, down 26% on a year ago.
  • It keeps 20 cents of each $1 of sales as operating profit, up from 9 cents a year earlier.
  • Spare cash over the past 12 months: $308 million, up from $224 million.
  • 1% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in 2 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$297m
March 2025$316m
June 2025$317m
September 2025$287m
December 2025$296m
March 2026$311m
June 2026$321m
September 2026$300m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024$35m
March 2025$23m
June 2025-$18m
September 2025$38m
December 2025$38m
March 2026$51m
June 2026$55m
September 2026$28m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
9 February 2027
Last annual report (10-K)
24 August 2026
Next quarterly (estimated, 10-Q)
5 February 2027

Who owns it

8 long-term investors we follow own it, up from 7 last quarter. 596 funds in all.

Jun '25
Dec '25
Jun '26

Sold out this quarter

Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

2 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 1 sold $437,187.

  • Herr Amy E.
    Director
    Sold
    Date
    8 May 2026
    Shares
    6,636
    Price
    $48.28
    Value
    $320,386
  • Herr Amy E.
    Director
    Sold
    Date
    17 February 2026
    Shares
    1,976
    Price
    $59.11
    Value
    $116,801

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 24 Aug 2026, plus the 10-Q filed 6 Nov 2026 and 3 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • It isn't cheap on profits: 47.1× operating profit.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.